Steven J Isakoff

Featured in: Favicon

nature.com Favicon

healio.com Favicon

futuremedicine.com

Articles

Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER) | npj Breast Cancer

Jan 6, 2025 | nature.com | Amy H. Comander |Steven J Isakoff |Beverly Moy |Seth A. Wander |Minetta C. Liu |Leif W. Ellisen

AbstractOptimal timing and dosing of adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor in early breast cancer is controversial. This prospective phase II clinical trial investigated tolerability and safety of two ribociclib dosing schedules.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →